3 ms·
I actually find this fascinating as it puts a dollar figure on it. It’s similar to the FDA priority voucher market. If you get a drug approved by the FDA for
by refurb 5y ago
I actually find this fascinating as it puts a dollar figure on it.
It’s similar to the FDA priority voucher market. If you get a drug approved by the FDA for a neglected disease, you get a transferable voucher that gets you a priority FDA review for whatever drug you use it for. It might accelerate approval by 3-6 months.
What’s that worth? Well the vouchers have sold for $100-250M lately.
https://www.fiercepharma.com/pharma/sanofi-nets-valuable-fda-voucher-approval-for-first-oral-regimen-for-neglected-sleeping https://www.fiercepharma.com/pharma/sanofi-nets-valuable-fda...
- HWR_14 5y ago> Well the vouchers have sold for $100-250M lately. Not to dismiss what you are saying, but "I can get regulatory approval for my drug faster" seems like it got far more valuable in the past, I dunno, 20-21 months or so.
- refurb 5y agoIf you’re referring to Covid vaccines I’m not sure the vouchers would have made much difference. The FDA moved as fast as possible.
- HWR_14 5y agoThe COVID vaccines took priority over everything (rightly so). But that meant that the FDA had less time to approve anything else, so priority still became more valuable.
- refurb 5y agoAhh.. but I’m pretty sure a public health emergency would negate the voucher anyways.
- HWR_14 5y agoI didn't mean the voucher would let you cut in front of the vaccine. The vaccine work didn't occupy 100% of the FDA. Let's say it ate up 75%. Well, the vouchers probably worked on the other 25%. And because there is a lot less available time, the vouchers are more valuable. I mean, imagine they have space for only one non-COVID review in 2020. Can you imagine how much that would be worth?